Emma Fröling

Emma Fröling

Auto-generated profile, based on publicly available information

Emma Fröling

Pfizer Pharma GmbH, Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Pharmaceutical Medicine
Verified
Journal Article
Open access
PDF file
EFEmma Fröling
Emma Fröling
NRNeda Rajaeean
Neda Rajaeean
KHKlara Sonnie Hinrichsmeyer
Klara Sonnie Hinrichsmeyer
DDDina Domrös-Zoungrana
Dina Domrös-Zoungrana
JUJohannes Nico Urban
Johannes Nico Urban
CLChristian Lenz
Christian Lenz
The advent of artificial intelligence (AI) revolutionizes the ways of working in many areas of business and life science. In Medical Affairs (MA) departments of the pharmaceutical industry AI holds great potential for positively influencing the medical mission of identifying and addressing unmet medical needs and care gaps, and fostering solutions that improve the egalitarian and unbiased access of patients to treatments worldwide. Given the essential position of MA in corporate interactions with various healthcare stakeholders, AI offers broad possibilities to support strategic decision-making and to pioneer novel approaches in medical stakeholder interactions. By analyzing data derived from the healthcare environment and by streamlining operations in medical content generation, AI advances data-based prioritization and strategy execution. In this review, we discuss promising AI-based solutions in MA that support the effective use of heterogenous information from observations of the healthcare environment, the enhancement of medical education, and the analysis of real-world data. For a successful implementation of such solutions, specific considerations partly unique to healthcare must be taken care of, for example, transparency, data privacy, healthcare regulations, and in predictive applications, explainability.

31 July 2025 in Journal of Medical Economics
Verified
Journal Article
Open access
CSConstanze Schmalhofer
Constanze Schmalhofer
EKEveline Otte Im Kampe
Eveline Otte Im Kampe
DEDirk Eheberg
Dirk Eheberg
HSHera Sandhu
Hera Sandhu
MMMartina Maier
Martina Maier
AKAgnes Kisser
Agnes Kisser
AimTo estimate the cost-effectiveness of Nirmatrelvir/ritonavir (NMV/r) versus best supportive care (BSC) in patients at high-risk for progression to severe COVID-19 from a German health payer perspective.MethodsA closed cohort static model of 1,000 COVID-19 patients capturing the short-term (<1 year) via decision-tree and long-term (lifetime) outcomes via Markov model was used to assess the cost-effectiveness of NMV/r versus BSC. Model inputs were derived from the EPIC-HR clinical trial and published contemporary real-world data. Probabilistic and deterministic sensitivity analyses (PSA, DSA) were conducted to test the robustness of model results.ResultsIn the base case, treatment with NMV/r versus BSC reduced COVID-19 related hospitalisations (-0.042), intensive care unit admissions (-0.006) and inpatient deaths (-0.003), while increasing life-years (LY) (0.047) per patient, which results in an incremental cost-effectiveness ratio of 10,845 €per hospitalisation avoided and 9,773 €per LY gained. Sensitivity analysis suggests the magnitude of the benefits increased with increasing hospitalisation risk. NMV/r emerged as the dominant strategy in a population with a hospitalisation risk equivalent to 60 years and older. Outcomes were similar with real world effectiveness data. DSA showed the model was most sensitive to hospitalisation and inpatient mortality risk, NMV/r medication cost and efficacy/effectiveness of NMV/r in reducing hospitalisation. PSA confirmed the robustness of the model results.LimitationsAs COVID-19 is a dynamic disease, caution should be taken in generalizing these results. Contemporary data is essential to ensure the model inputs and the outcomes remain relevant as there may be changes in natural disease course or effectiveness of NMV/r.ConclusionsThis cost-effectiveness analysis of NMV/r treatment from a German healthcare payer perspective demonstrates how by preventing progression to severe COVID-19, NMV/r reduces healthcare resource use, associated costs and preserves LY of patients. This analysis provides crucial economic rationale for decision making by policy makers.

13 March 2026 in Journal of Neurology
Verified
Journal Article
Open access
EFEmma Fröling
Emma Fröling
MSMariel Morales Sahm
Mariel Morales Sahm
MSMarcel Schmude
Marcel Schmude
CACharlotte P. Assies
Charlotte P. Assies
MWMichael Wittenberg
Michael Wittenberg
TRThomas Günther Riemer
Thomas Günther Riemer
Objective: To synthesize adverse event (AE) data from randomized controlled trials (RCTs) of levetiracetam (LEV) and brivaracetam (BRV), compare their safety profiles, and identify moderators of AE risk. Methods: We conducted a systematic review and meta-analysis of RCTs of LEV or BRV, searching PubMed, Web of Science, and ClinicalTrials.gov to August 2025. AE frequencies were summarized qualitatively, and random-effects meta-analyses compared LEV and BRV with placebo. Additional analyses compared LEV and BRV and assessed moderators. PROSPERO: CRD42023491050, CRD420251003207. Results: Ninety-six RCTs including 7145 patients exposed to LEV and 2549 to BRV were analyzed. Qualitative synthesis identified headache, somnolence, dizziness, and fatigue as the most common AEs, with higher frequencies of some psychiatric AEs (e.g., irritability, aggression) reported for LEV. Meta-analyses showed increased somnolence with both LEV (OR 1.80, 95% CI [1.41–2.30]) and BRV (OR 1.86, 95% CI [1.33–2.61]). LEV was additionally associated with irritability (OR 2.55, 95% CI [1.41–4.63]) and asthenia (OR 1.71, 95% CI [1.15–2.54]), whereas BRV was associated with dizziness (OR 1.75, 95% CI [1.24–2.46]) and fatigue (OR 2.14, 95% CI [1.43–3.20]). Few moderators of AE risk were identified, and no significant differences emerged between LEV and BRV in indirect comparisons. Conclusion: LEV and BRV show favorable safety profiles that appear comparable based on meta-analytic findings, despite higher rates of some psychiatric AEs with LEV on a descriptive level. Both remain safe treatment options, though larger head-to-head trials are needed to provide definitive comparative evidence.

21 October 2026 in Journal of Health Economics and Outcomes Research
Verified
Journal Article
Open access
PDF file
DGDaniel Gensorowsky
Daniel Gensorowsky
EFEmma Fröling
Emma Fröling
KBKylie Braegelmann
Kylie Braegelmann
JDJana Diekmannshemke
Jana Diekmannshemke
AKAgnes Kisser
Agnes Kisser
EKEveline Otte Im Kampe
Eveline Otte Im Kampe
Background: Evidence on the economic burden of post-COVID syndrome in Germany remains limited. This study quantifies post-COVID-associated healthcare resource utilization (HCRU), sick leave, and costs. Objectives: To compare HCRU, sick leave, and costs borne by the statutory health insurance (SHI) among incident pediatric and adult post-COVID patients with matched post-COVID-free controls. Methods: This retrospective cohort study analyzed an anonymized German SHI claims database provided by GWQ ServicePlus AG. The observation period spanned October 2021 to June 2025 and included all individuals with incident COVID-19 diagnosis until September 2024. Incident post-COVID was defined as the first ICD-10-GM code (U07.4!; U09.9!) recorded ≥90 days after first COVID-19 diagnosis. Post-COVID cases were exactly matched 1:2 to post-COVID–free COVID-19 controls by calendar quarter of incident COVID-19 diagnosis, acute severity, cohort entry quarter, 5-year birth interval, sex, and Elixhauser Comorbidity Index. We estimated mean differences in HCRU, sick leave, and direct SHI-borne costs per case. Rate ratios of HCRU, sick leave, and costs per person-year were estimated using Poisson (HCRU/sick leave) and linear (costs) regression. Analyses covered 365-day, 730-day, and any follow-up period. Results: We matched 25 485 identified post-COVID cases with 49 671 controls. Matched cases and controls were comparable in age, sex, and comorbidities. Overall, during 365 days of follow-up, post-COVID patients showed higher HCRU and sick leave rates across all sectors, especially sick leave days. Mean differences per case were greatest for sick leave days (365 days: +27 days) and outpatient physician contacts (365 days: 6.9 contacts). HCRU and sick leave rates remained significantly increased over extended follow-up periods. Total SHI-borne costs per person-year were higher among post-COVID patients across all follow-up periods (all P < .001). Sector-specific costs per person-year were increased primarily in the outpatient sector and for sickness benefits (all P < .001). Mean total cost differences per case were +€1806 per case (365 days) and mean excess sickness benefits per case were +€1077. Conclusions: Documented post-COVID was associated with a substantial and sustained economic burden on the German healthcare system and society. Targeted strategies are needed to mitigate potential long-term impacts on HCRU and labor productivity.